Topic: disease awareness

October 28th, 2015

Janssen Recognizes World Psoriasis Day

This October 29th, the Janssen Pharmaceutical Companies of Johnson & Johnson join the International Federation of Psoriasis Associations in support of World Psoriasis Day, an annual event dedicated to raising awareness of an autoimmune disease that affects 125 million people worldwide.

At Janssen, our commitment to people living with psoriatic disease has never been stronger, both through the medicines that we offer today and through our continued research and development to advance the next generation of therapies for the future.

We are motivated to go further by the personal impact of psoriasis and psoriatic arthritis, pursuing approaches that will hopefully one day intercept and even prevent psoriatic disease altogether.

Every day, these efforts bring us closer to realizing our vision of #aworldfreefrom immune and inflammatory diseases, an aspirational goal but one that we believe is achievable for people living with or who may develop psoriatic disease in the future.

Anne Fourie2

Anne Fourie, PhD, is Disease Area Leader, Psoriasis, Janssen Research & Development, LLC



irene HsuIrene Hsu, PharmD, MBA, is Vice President, Commercial Disease Area Leader, Rheumatoid Arthritis and Psoriasis, Janssen Pharmaceutical Companies of Johnson & Johnson.




Read More

October 11th, 2015

Janssen Recognizes World Arthritis Day

Today, October 12th, the Janssen Pharmaceutical Companies of Johnson & Johnson stand with the European League Against Rheumatism in support of World Arthritis Day, an annual event to raise awareness of rheumatic and musculoskeletal diseases.

At Janssen, we understand the impact that conditions like rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis have each and every day on patients and their loved ones. For the past twenty years, we have made it our mission to address these challenges through the development of advanced biologic therapies. While these important medicines have changed the way these diseases are treated, we still strive to do for more patients.

Today, our scientists are advancing the latest research to discover and develop the next generation of medicines that will provide new, more personalized approaches in addressing individual patient needs. We look to the future, motivated by the successes we have seen over the years, and inspired by the challenges we recognize still exist for many people living with the pain, inflammation and limitations associated with rheumatic diseases.

As we look to the future, we envision #aworldfreefrom immune and inflammatory diseases like RA. That’s our vision and, today, on World Arthritis Day, our global Janssen team is taking action in advancing science to help those living with rheumatic and musculoskeletal diseases today and in the future.

Read More

October 9th, 2015

Prostate Cancer: Living, Not Just Surviving

By Jane Griffiths, Company Group Chairman, Janssen EMEA and Executive Sponsor, Janssen Sustainability Council

Janssen report focuses on quality of life for prostate cancer survivors

Prostate Cancer: Living, Not Just SurvivingMore than three million men in Europe have prostate cancer and almost half of them have lived with the disease for five years or more, according to European Commission. Advances in the management of prostate cancer means that more patients are beating the disease and looking ahead at what it means to live as a survivor.

To bring focus to the issues facing prostate cancer survivors, the team at Janssen recently launched the Prostate Cancer: Living, not Just Surviving report, summarizing findings of a pan-European survey of prostate cancer patients, caregivers and healthcare professionals looking at the physical, emotional and social impact of prostate cancer. Some key findings in the report include:[i]

  • Fatigue (66%) has the biggest negative impact on patients reporting chronic physical effects from the disease, over disability and pain (41% and 22% respectively)
  • Prostate cancer patients are more likely to worry about intimacy problems (54%) than dying (36%), however nearly two-thirds (62%) of patients are not willing to talk about such intimacy problems with their partner
  • In prostate cancer patients:
    • 80% are unable to do activities they used to enjoy before diagnosis
    • 85% are unable to be intimate with their partner following diagnosis
  • Only 14 percent of healthcare professionals feel that they have sufficient resources to address these types of quality of life issues

This launch is the culmination of more than two years’ work, involving many patient organisations from across Europe.

Read More

October 5th, 2015

Policies that Underestimate NCDs Could Blunt Economic Growth in Asia

By Kris Sterkens, Company Group Chairman, Janssen, the pharmaceutical companies of Johnson & Johnson, Asia Pacific

A new report from the EcoShifting Landscape of HC in AP_Page_1nomist – The Shifting Landscape of Healthcare in Asia Pacific confirms that people in our region are living longer, but not necessarily healthier, with overburdened, provider-led healthcare systems that lack comprehensive strategies to address emerging non-communicable diseases (NCDs) such as cancer, diabetes and mental illness.

We provided a grant for the development of this independent research report, which examines whether current health policies in Australia, China, India, Japan and South Korea are coping with the sharp rise of NCDs while these countries continue to tackle an existing burden of infectious diseases, such as tuberculosis and hepatitis.

There is a quote in the report by Professor Aikichi Iwamoto, chair of Japan’s National HIV Surveillance Committee, who notes that one difficulty in dealing with the HIV/AIDS epidemic in much of Asia is that “health systems in many countries are more adjusted to acute infections where people are cured by antimicrobials in five days.”

This accurately captures the history of a region that has endured deadly emergency outbreaks of viruses and influenzas for more than a century, most recently with SARS and Avian Flu.

Read More

September 28th, 2015

Janssen Teams Up With Sports Stars For AFib Awareness

Editor’s note: Atrial fibrillation, or AFib, is a type of irregular heart beat. It can sometimes be felt as a fluttering or “thumping” in the chest. Since the heart isn’t pumping properly, blood may pool in the upper chambers and form a clot. This clot can break free, travel to the brain, and cause a stroke.

In honor of AFib Awareness Month, 39-Time Grand Slam Tennis Champion Billie Jean King and 14-Time Basketball All-Star Jerry West are working with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to help raise awareness about this health condition. Below, they share their stories. Plus, read on for a simple tool to help you evaluate your risk.

Jerry’s Story

When I hit the court as a Los Angeles Laker, I loved the feeling of making a game-winning play and knowing I was on top of my game. But when I had to start breathing into a paper bag during games to keep from hyperventilating and my heart felt out-of-rhythm, I knew something was wrong. It wasn’t until after I stopped playing professional basketball that I was diagnosed with atrial fibrillation (AFib), an irregular heartbeat and one of the most common serious heart rhythm disorders in people over the age of 65.

Read More

June 16th, 2015

Cancer and Clots: An Unrecognized and Under-Researched Patient Burden

By Paul Burton, MD, PhD, Vice President, Medical Affairs, Janssen

More than one-third of all men and women in the United States will be diagnosed with cancer over the course of their lives. Living with cancer, the treatments and their side effects are significant burdens on their own. What many people with cancer often don’t realize is they are up to five times more likely to develop life-threatening blood clots than people the same age without cancer. These clots can occur deep in the veins in many parts of the body and sometimes travel to the lungs, a condition called venous thromboembolism (VTE). This risk is even more pronounced when patients with cancer undergo chemotherapy.

Blood clots are the second-leading cause of death in patients with cancer. We need a better understanding of how we can treat and prevent them, particularly for a large number of the one million patients who are treating their cancer outside the hospital.

That’s why the Janssen Pharmaceutical Companies of Johnson & Johnson, in conjunction with Bayer HealthCare, are furthering our commitment to addressing the most important unmet medical needs of our time by initiating a new research program: CALLISTO. CALLISTO is aimed at generating new evidence in the prevention and treatment of blood clots in patients with a wide range of cancer types.

Read More

May 19th, 2015


Janssen Recognizes World IBD Day

By Scott Plevy, M.D., Disease Area Stronghold Leader, Inflammatory Bowel Disease (IBD), and Sean Larkin, Disease Area Stronghold Commercial Leader, IBD, Janssen

 Today, May 19th, the Janssen Pharmaceutical Companies of Johnson & Johnson recognize World Inflammatory Bowel Disease (IBD) Day, an annual event to raise awareness and support the five million people living with Crohn’s disease and ulcerative colitis (UC).

At Janssen, we work each and every day to improve the lives of people living with Crohn’s disease and UC—a passion that’s inspired us for more than two decades.

Guided by the conviction that there are no limits to science, we recognize that, despite our successes, we can do more for patients. As innovators and collaborators, we are committed to treating, intercepting and, one day, curing IBD.

We hope that you support World IBD Day and join the conversation on Twitter and LinkedIn by sharing what a world free from IBD means to you using #aworldfreefrom.

ScottPlevyJNJScott Plevy, M.D., is Vice President, Disease Area Stronghold Leader, IBD, Immunology Therapeutic Area, Janssen Research & Development, LLC.



Sean Larkin - Immunology - Comm DAS Lead_jpgSean Larkin is Vice President, Disease Area Stronghold Commercial Leader, Pulmonary and IBD, Janssen Global Services, LLC.

Read More

December 11th, 2014

Johnson & Johnson and USAID Partner to Address the Global Health Threat of Antibiotic-Resistant Bacteria

by Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

Among my lifelong goals is to advance progress in new treatment options for patients living with the world’s most serious health threats. Antimicrobial resistance is responsible for many of them, especially in communities with limited resources and fragmented healthcare infrastructures. When resistance limits first- and second-line options, healthcare providers must opt for less desirable alternatives,1 which often lead to worsened patient outcomes.

Over many years of researching and learning, the complexities of infectious diseases have become clear to me. Despite the development of new treatments to address ever-expanding forms of antimicrobial resistance, the ability to scale up appropriate use of treatment regimens remains challenging.

According to the 2013 Antibiotic Resistance Threats in the United States report, approximately 250,000 antimicrobial infections each year require hospitalization, or are already affecting hospitalized patients, who also already have weakened immune systems.1 These infections should command our complete attention especially because the threat can reach us all – almost half of infections occur in people younger than 65, and more than 90 percent of deaths occur in people 65 and older.1

Given the hardships of combating antimicrobial resistance, we are proud to announce our pharmaceutical company, Janssen, has signed a memorandum of understanding (MOU) for a collaboration with the United States Agency for International Development (USAID) to help address the global health threat of antibiotic-resistant bacteria.

Read More

November 19th, 2014

Supporting World COPD Day

World COPD Day Infographic

Today, November 19th, Janssen proudly supports World Chronic Obstructive Pulmonary Disorder (COPD) Day, an annual event organized by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to raise awareness and improve care for obstructive lung diseases.

COPD is a progressive lung disease that interferes with airflow, making it difficult to breathe. Emphysema and chronic bronchitis are terms often used to describe types of COPD. More than 64 million people worldwide are living with COPD, and while core symptoms include cough, phlegm, and shortness of breath it can be life threatening. In fact, the World Health Organization estimates that COPD will become the third-leading cause of death globally by 2030. This staggering statistic speaks volumes, especially considering that COPD is treatable, although not curable.

At Janssen, we have made great strides to deepen our understanding of patient needs and build a strong network of skilled scientists and experts with deep disease understanding, while seeking collaborative efforts to develop future treatments that are safe, effective and accessible for patients. With a portfolio of promising therapies, Janssen strives to go beyond the current standard of care to not only treat the core symptoms of disease, but one day stop disease progression or even prevent COPD.

Read More

November 6th, 2014

Ebola: What Nurses Must Know

by Andrea Higham, Senior Director, Corporate Equity, Johnson & Johnson

Ebola Nurses.comSince the first case of Ebola hit U.S. shores, the nation’s frontline caregivers — registered nurses — have appealed for information about disease. The Johnson & Johnson Campaign for Nursing’s Future is happy to respond to this important need by launching an initiative to educate every nurse in America about Ebola.

An educational grant provided by the Campaign to our partner offers nurses the opportunity to learn how to properly identify patients with Ebola in any healthcare setting, as well as the precautions nurses must follow to protect themselves while treating patients with the disease. Through the grant, nurses can complete a one-hour continuing education course on the screening, clinical treatment and special precautions surrounding the disease. In addition, nurses can extend their learning experience by accessing a unique digital publication devoted entirely to the CE course, resources and news about Ebola for three hours of CE credit.

For more than a decade, we have been pleased to partner with, a leading provider of CE for nurses in the U.S., to bring vital learning opportunities to the nation’s largest group of healthcare providers. Together, our organizations have provided CE programming to nurses on topics ranging from career and leadership development to response to natural disasters.

Read More